申请人:Kyoto Pharmaceutical Industries, Ltd.
公开号:US04943567A1
公开(公告)日:1990-07-24
Cephalosporin compounds represented by the general formula (I): ##STR1## wherein R.sup.1 and R.sup.5 independently represent a hydrogen atom or a protective group for an amino group; R.sup.2 represents an alkyl group or a cycloalkyl group; R.sup.3 represents a hydrogen atom, a lower alkenyl group, an alkanoyloxymethyl group, a carbamoyloxymethyl group, a heterocyclic thiomethyl group or a heterocyclic methyl group; R.sup.4 represents a hydrogen atom or an ester residue; and X represents CH or a nitrogen atom and pharmacologically acceptable addition salts thereof, intermediate compounds used in the synthesis process of these compounds, production methods of these compounds and pharmaceutical compositions containing these compounds. Said compounds or addition salts thereof exhibit noticeable antibacterial activities even on Pseudomonas aeruginosa, on which known cephalosporin compounds do not exhibit antibacterial activities, and moreover, work well against ordinary Gram-positive bacteria and Gram-negative bacteria.
头孢菌素化合物的一般公式(I)代表的头孢菌素化合物:其中R.sup.1和R.sup.5独立地代表氢原子或氨基的保护基团;R.sup.2代表烷基或环烷基;R.sup.3代表氢原子、较低的烯基基团、烷酰氧甲基基团、氨甲酰氧甲基基团、杂环硫甲基基团或杂环甲基基团;R.sup.4代表氢原子或酯基残基;X代表CH或氮原子及其药理学上可接受的加合盐,用于这些化合物的合成过程中使用的中间化合物,这些化合物的生产方法以及含有这些化合物的药物组合物。所述化合物或其加合盐在偏光绿脓杆菌上表现出显着的抗菌活性,而已知的头孢菌素化合物在偏光绿脓杆菌上并不表现出抗菌活性,而且对普通的革兰氏阳性细菌和革兰氏阴性细菌也有良好的作用。